IndraLab

Statements


| 1 27

reach
"Specifically, empagliflozin was demonstrated to prevent ROS production stimulated by the proinflammatory cytokine IL-17 and to attenuate inflammatory signaling via NLRP3/caspase-1-dependent mitogenic and migratory proinflammatory cytokines IL-1β and IL-18 in SMCs [125]."

reach
"Empagliflozin inhibits NLRP3 inflammasomes, but the mechanism was likely associated with the regulation of ketones and insulin levels (Kim et al., 2020) or in a Ca 2+ -dependent manner (Byrne et al., 2020) ."

reach
"As a hypoglycemic agent, in addition to lowering blood sugar and reducing the incidence of cardiovascular events in diabetic patients, empagliflozin was also reported to inhibit the activation of the NLRP3 inflammasome, thus reducing cardiac inflammation and preserving cardiac function via a Ca -dependent mechanism (131)."

reach
"Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis."

reach
"Furthermore, empagliflozin treatment reduced the elevated inflammatory molecule, NLRP3 in D-gal-treated HUVECs ."

reach
"11 An in vitro study pointed out that empagliflozin exerts an antioxidant effect in cardiac myocytes by decreasing Dox-induced lipid peroxidation in cardiac myocytes.10 Besides, Quagliariello et al. discovered in vivo that empagliflozin inhibited inflammation, apoptosis, fibrosis, and ferroptosis in Dox-induced mice via the NLRP3- and MyD88-related pathways, thereby greatly improving cardiac functions.12 Hence, it could be concluded from the above that empagliflozin may have the effect of alleviating Dox-induced cardiotoxicity."

reach
"71 Metformin and empagliflozin, two well-known antidiabetic drugs, inhibited NLRP3 inflammasome and decelerated the development of diabetic cardiomyopathy but via different mechanisms."
| PMC

reach
"In addition, empagliflozin can degrade the inflammatory component NLRP3 through selective autophagy and reduce the maturation and secretion of inflammatory factors (140)."

reach
"Empagliflozin given in an animal model of HFpEF led to reduced NLRP3 activation [188], which in turn leads to a reduction in IL-1β levels and so increases SERCA2a function."

reach
"In a study, it has also been reported that empagliflozin (another SGLT-2 inhibitor) inhibits the activation of NLRP3 inflammasome and attenuates the downstream inflammatory response in the diabetic ki[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"In ex vivo experiments with macrophages stimulated with ATP, it has been observed that empagliflozin can attenuate NLRP3 activation [66]."

reach
"Similarly, Benetti et al. demonstrated that empagliflozin significantly reduces diabetic renal NLRP3 inflammasome activity and attenuates downstream inflammatory responses [100]."

reach
"Empagliflozin (a different SGLT-2 inhibitor) has also been determined to impede the kindling of NLRP3 inflammasome and decrements downstream inflammatory signaling in the diabetic kidneys in another study [17]."

reach
"In an animal study, empagliflozin decreased cardiac lipid accumulation by inhibiting the NLRP-3 inflammasome signal pathway [ 14 ]."

reach
"Empagliflozin was also demonstrated to inhibit NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in a Ca -dependent manner in both isolated mouse hearts and human cardiomyocytes."

reach
"Empagliflozin attenuates heart failure in experimental models of heart failure without DM by lowering intracellular Ca and suppressing NLRP3 [78]."

reach
"In T2DM and cardiovascular disease patients, Kim et al. [63] found that empagliflozin inhibited the NLRP3 inflammasome regardless of glycemic control."

reach
"A study showed that empagliflozin reduced the activation of NLRP3 inflammasome and attenuated pyroptosis caused by NLRP3 inflammasome in diabetic mice."

reach
"Experimental data disclosed that empagliflozin might downregulate the NLRP3 inflammasome, and this result was AMPK-dependent and SGLT2/glucose-lowering independent [72]."

reach
"Of note, empagliflozin attenuated activation of the NLRP3 inflammasome and expression of associated markers of sterile inflammation in hearts from mice with HFrEF, implicating reduced cardiac inflammation as a mechanism of empagliflozin that contributes to sustained function in HFrEF in the absence of diabetes mellitus."

reach
"More specifically, Ye et al. demonstrated that by inhibiting the NLRP3 inflammasome, empagliflozin produced protection against obesity-related kidney disease."

reach
"It was also proposed that empagliflozin reduced NLRP3 inflammasomes, possibly secondary to inhibition by increased circulating ketone metabolites, β-hydroxybutyrate [64]."

reach
"Interestingly, empagliflozin appears to lead to suppression of the NLRP3 inflammasome by reducing intracellular calcium [110], which further supports the role of SGLT2 inhibition in sodium-calcium homeostasis (as will be further detailed below)."

reach
"In HF rodent models, empagliflozin inhibited NLRP3 inflammasome in a Ca 2+ -dependent manner [284] ."

eidos
"Byrne et al. ( 2020 ) showed that empagliflozin attenuated the NLRP3 level and then mitigated the inflammatory response in mice with HF , reducing cardiac fibrosis and remodeling ."

reach
"Empagliflozin attenuated the activation of NLRP3 inflammasome in a Ca 2+ -dependent manner XREF_BIBR."

reach
"Consistent with the class effect of the SGLT2i in clinical studies [ 18 , 103–106 ], the late-I Na inhibitory effects of SGLT2i are also a drug class effect, as empagliflozin- dapagliflozin- and canag[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"Daily treatment of ulcerative rats with empagliflozin significantly reduced NLRP3 protein and mRNA expressions."